melanoma

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

A EFFACER

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive
nivolumab
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting

All mechanism

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive
nivolumab
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting

B-Raf enzyme inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting
vemurafenib
BRIM 8, 2018      NCTvemurafenibplaceboadjuvantsuggesting
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting

combined BRAF-MEK inhibitors

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting

immune checkpoint inhibition

ipilimumab
Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias conclusive
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias suggesting
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias suggesting
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive
nivolumab
CheckMate 037 (Weber), 2015      NCTnivolumabchemotherapy2L, anti-CTLA-4 failure 2nd line Risk of bias suggesting
CheckMate 066 (Robert), 2015      NCTnivolumabdacarbazine1L 1st line Low risk of bias conclusive
CheckMate 238, 2017      NCTnivolumabipilimumabadjuvant adjuvant Low risk of bias conclusive
CheckMate 067 (nivo vs ipi), 2015      NCTnivolumabipilimumab1L 1st line Low risk of bias conclusive
CheckMate 067 (nivo + ipi vs ipi), 2015    NCTnivolumab + ipilimumabipilimumab1L 1st line Low risk of bias conclusive
Postow, 2015      NCTnivolumab + ipilimumabipilimumab1L 1st line Exploratory -
CheckMate 067 (nivo + ipi vs nivo), 2015      NCTnivolumab + ipilimumabnivolumab1L 1st line Exploratory -
pembrolizumab
KEYNOTE 002 (10mg/kg Q3W), 2015      NCTpembrolizumab 10mg/kgchemotherapy2L 2nd line Exploratory suggesting
KEYNOTE 002 (2mg/kg Q3W), 2015      NCTpembrolizumab 2mg/kgchemotherapy2L 2nd line Exploratory suggesting
KEYNOTE-006 (every 2W), 2015      NCTpembrolizumab (every 2W)ipilimumab1L 1st line Risk of bias suggesting
KEYNOTE-006 (every 3W), 2015      NCTpembrolizumab (every 3W)ipilimumab1L 1st line Risk of bias suggesting
KEYNOTE-001, 2014      NCTpembrolizumab 2mg/kgpembrolizumab 10mg/kg2L 2nd line Exploratory negative
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive

interferon

Interferon alpha
EORTC18952 (Eggermont), 2005   ID IFN alpha-2b (I M)observationadjuvantnegative
Nordic IFN Trial, 2011     ID IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18871/DKG 80-1 (Kleeberg), 2004   rIFN alpha-2bobservationadjuvantnegative

MEK inhibitor

encorafenib plus binimetinib
COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting
selumetinib
Kirkwood, 2012     selumetinibtemozolomide -
Kirkwood   selumetinibtemozolomide -
trametinib + dabrafenib
Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting
vemurafenib and cobimetinib
Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting

Miscellaneous

Interferon alpha
EORTC18991 (Eggermont), 2008   PEG IFN alpha-2b (I M)observationadjuvantsuggesting
EORTC18871/DKG 80-1 stage III   rIFN alpha-2bobservation -
ipilimumab
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive
nivolumab
CheckMate 238 subgroup IIIB-C   nivolumabipilimumabsuggesting
pembrolizumab
KEYNOTE-054, 2018      NCTpembrolizumabplaceboadjuvant adjuvant Low risk of bias conclusive
trametinib + dabrafenib
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting
vemurafenib
BRIM 8 (cohort IIIC)   vemurafenibplacebonegative